Table 2.

Post-COVID neuropsychological manifestations 12 weeks after the primary COVID-19

Symptom	Fluvoxamine (n = 42)	Placebo (n = 43)	P-value*	Relative Risk
Primary outcome
Fatigue	9 (21.4%)	19 (44.2%)	0.026	0.48 (0.25–0.95)
Secondary outcome
Headache	3 (7.1%)	6 (14%)	0.483	0.51 (0.14–1.91)
Memory impairment	2 (4.8%)	5 (11.6%)	0.433	0.41 (0.08–1.99)
Poor concentration	8 (19%)	7 (16.3%)	0.738	1.17 (0.46–2.93)
Insomnia	9 (21.4%)	10 (23.3%)	0.840	0.92 (0.41–2.03)
Aggression	1 (2.4%)	4 (9.3%)	0.360	0.25 (0.03–2.19)
Anxiety	8 (19%)	13 (30.2%)	0.232	0.63 (0.29–1.36)
Depression	1 (2.4%)	7 (16.3%)	0.058	0.14 (0.02–1.13)
Distorted Taste	3 (7.1%)	8 (18.6%)	0.115	0.38 (0.11–1.34)
Distorted Smell	6 (14.3%)	11 (25.6%)	0.193	0.56 (0.22–1.37)
Myalgia	5 (11.9%)	7 (16.3%)	0.563	0.73 (0.25–2.12)
PCS	32 (76.2%)	35 (81.4%)	0.557	0.93 (0.75–1.16)

PCS Post-COVID syndrome

^* Statistically significant p-values are bolded